Plain-English translation of NCT06208150 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether — a newer type of cancer-fighting medication — works better when combined with other drugs compared to current standard treatments for multiple myeloma that has become resistant to previous therapies. About 795 people will be randomly assigned to receive one of three different drug combinations. The goal is to find out which combination helps people live longer and control their cancer best.
Multiple myeloma often becomes resistant to initial treatments, leaving patients with limited options. This trial is designed to see whether these newer medications can offer better results and give patients with hard-to-treat disease a more effective path forward.
If you join this trial, you'll be randomly assigned to one of three treatment groups. One group receives injections combined with oral pills, another receives two injectable medications together, and a third receives standard treatments chosen by your doctor. You'll visit the clinic regularly for injections, blood tests, and monitoring. The study continues as long as the treatment is helping and you're tolerating it well, with follow-up visits to track your progress and any side effects.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States